Is Pfizer stock a buy after the CDC recommended Covid booster shots for people age 65 and older, and otherwise vulnerable Americans?
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting
The 4% rule, a popular theory, says one can safely spend down 4% of their portfolio annually, increasing each year with inflation, during one’s retirement. The participants were John Rekenthaler and Hong Cheng of Morningstar, Jonathan Guyton of Cornerstone Wealth Advisors, and Michael Finke of the American College of Financial Services. Before I get into what they said, I want to share my perspective on the topic of spending in retirement.
Discover four of the best-performing mutual funds managed and administered by Franklin Templeton Investments that invest in equities and fixed income securities.
(Bloomberg) -- Think the selloff in technology stocks has been bad? If U.S. Treasury yields keep rising, it’s probably going to get worse. Most Read from BloombergThe Country That Makes Breakfast for the World Is Plagued by Fire, Frost and DroughtHSBC Bets Big on China as Pressure Mounts in LondonHow Los Angeles Became the City of DingbatsThe Unstoppable Appeal of Highway ExpansionWhy the Gaza Strip May Be the City of the FutureThat’s the widespread thinking on Wall Street as the surge in yields
In the latest trading session, Pfizer (PFE) closed at $43.57, marking a -0.84% move from the previous day.
Sep.27 -- President Joe Biden receives a booster shot of the Pfizer Inc.-BioNTech SE Covid-19 vaccine at the White House on Monday.
- Motley Fool
Big pharma company Pfizer (NYSE: PFE) has been around for more than 170 years. Pfizer last year partnered with German biotech BioNTech and won the first Emergency Use Authorization for a coronavirus vaccine. At the same time, Pfizer stock hasn't exactly soared.
- The Wall Street Journal
Beijing may eventually capitulate and take a step back on its emission control measures, but skyrocketing coal prices mean many Chinese power plants are operating at lower margins or even at a loss.
Acceleron produces a drug to treat pulmonary arterial hypertension and Reblozyl, used against blood-related disorders.
- Yahoo Finance Video
Brian Sozzi, Julie Hyman, and Brian Cheung break down Monday’s trending tickers which include: Tesla shareholders receiving a recommendation to reject Kimbal Musk and Murdoch as board members, Morgan Stanley cutting Amazon’s price target as concerns over the company’s profitability take center stage, and Polestar partnering with Gores Guggenheim in a SPAC deal to go public.
iFit Health & Fitness plans to trade on the Nasdaq under the ticker IFIT. The company is scheduled to price its deal on Tuesday, Oct. 5.
- WISN - Milwaukee Videos
Dr. Bill Hartman from UW Health speaks about who should get COVID-19 booster shots and when children will be eligible to receive the vaccine.
- Investor's Business Daily
Is Moderna stock a buy after the Pfizer and BioNTech win FDA approval for their rival Covid shot? Is MRNA stock a buy right now?
- FX Empire
The stock made an attempt to settle below $3,340.
Insiders are neutral on the overall stock market’s prospects over the next 12 months. That’s a significant improvement from where they stood in January.
India's antitrust watchdog has agreed to Google's request to keep confidential some information the company provided during an investigation into its business, though the regulator denied allegations it leaked a report on the probe to the media, a judge said on Monday. Alphabet Inc's Google sued the Competition Commission of India (CCI) at a New Delhi court last week, urging a judge to direct the watchdog to prevent leaks of information. The filing came after The Times of India and Reuters reported this month, citing a confidential CCI report, that the regulator's probe had found that the U.S. tech giant abused the dominant position of its Android operating system in India, unfairly using its "huge financial muscle" to hurt competitors.
Two U.S. senators said on Tuesday a Facebook Inc whistleblower will testify at a Senate hearing next week about what one of them called the social media company's "toxic effects" on young users. "This whistleblower’s testimony will be critical to understanding what Facebook knew about its platforms' toxic effects on young users, when they knew it, and what they did about it," Democratic Senator Richard Blumenthal, head of a subcommittee of the Senate commerce panel, said in a statement announcing the Oct. 5 hearing.
- Insider Monkey
Harding Loevner, an investment management firm, published its “Global Small Companies Equity Fund” second-quarter 2021 investor letter – a copy of which can be downloaded here. A quarterly net return of 6.82% was recorded by the fund for the Q2 of 2021, beating its Benchmark, the MSCI All Country World Small Cap Index, which returned […]
- Motley Fool
ARK Invest added to two of her newer positions, and it added to a third stake of a stock that has shed nearly half of its peak value.
- Coin Rivet
The Central Bank of Nigeria’s eNaira website has gone live ahead of schedule. And, in the 24 hours following the launch, it received more than a million hits.
After a full year of market gains, markets are getting a bit nervous. Inflation is up, US job openings are exceeding the number of unemployed by record amount, and the pile-up of container ships on the West Coast is a continuing reminder that supply chains have not yet recovered from the pandemic disruptions. Taking the measure of current conditions, Jefferies’ global equity strategist Sean Darby lays out the worst case scenario: “…if breakeven inflation expectations were to fall, narrowing real